These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1310 related articles for article (PubMed ID: 36717905)

  • 1. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.
    Maalej KM; Merhi M; Inchakalody VP; Mestiri S; Alam M; Maccalli C; Cherif H; Uddin S; Steinhoff M; Marincola FM; Dermime S
    Mol Cancer; 2023 Jan; 22(1):20. PubMed ID: 36717905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
    Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances.
    Zhang T; Tai Z; Miao F; Zhang X; Li J; Zhu Q; Wei H; Chen Z
    J Control Release; 2024 Apr; 368():372-396. PubMed ID: 38408567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
    Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
    J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies.
    Wang H; Pan W
    Mol Cell Biochem; 2023 May; 478(5):967-980. PubMed ID: 36190614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
    Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
    Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment.
    Portillo AL; Monteiro JK; Rojas EA; Ritchie TM; Gillgrass A; Ashkar AA
    Front Immunol; 2023; 14():1286750. PubMed ID: 38022679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.
    Nikoo M; Rudiansyah M; Bokov DO; Jainakbaev NT; Suksatan W; Ansari MJ; Thangavelu L; Chupradit S; Zamani A; Adili A; Shomali N; Akbari M
    J Cell Mol Med; 2022 Aug; 26(15):4137-4156. PubMed ID: 35762299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies.
    Zhao D; Zhu D; Cai F; Jiang M; Liu X; Li T; Zheng Z
    Technol Cancer Res Treat; 2023; 22():15330338231204198. PubMed ID: 38037341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.
    Keshavarz A; Salehi A; Khosravi S; Shariati Y; Nasrabadi N; Kahrizi MS; Maghsoodi S; Mardi A; Azizi R; Jamali S; Fotovat F
    Stem Cell Res Ther; 2022 Sep; 13(1):482. PubMed ID: 36153626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic treatment strategy: combining CAR-NK cell therapy and radiotherapy to combat solid tumors.
    He J; Yan Y; Zhang J; Wei Z; Li H; Xing L
    Front Immunol; 2023; 14():1298683. PubMed ID: 38162672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem.
    Gatto L; Franceschi E; Di Nunno V; Maggio I; Lodi R; Brandes AA
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1333-1353. PubMed ID: 34734551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
    Sloas C; Gill S; Klichinsky M
    Front Immunol; 2021; 12():783305. PubMed ID: 34899748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
    Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments.
    Li X; Li W; Xu L; Song Y
    Chin Med J (Engl); 2024 Jun; 137(11):1285-1302. PubMed ID: 37640679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.
    Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S
    Cells; 2021 Apr; 10(5):. PubMed ID: 33925968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR-NK cell in cancer immunotherapy; A promising frontier.
    Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
    Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy.
    Kilgour MK; Bastin DJ; Lee SH; Ardolino M; McComb S; Visram A
    Front Immunol; 2023; 14():1166038. PubMed ID: 37205115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies.
    Marofi F; Saleh MM; Rahman HS; Suksatan W; Al-Gazally ME; Abdelbasset WK; Thangavelu L; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Pathak Y; Naimi A; Baradaran B; Nikoo M; Khiavi FM
    Stem Cell Res Ther; 2021 Jul; 12(1):374. PubMed ID: 34215336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.